Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Innovation Council · Finished

APAC-ON APAC – the first targeted therapy for peripheral arterial occlusive disease.

Coordinator
Aplagon Oy, Finland
Runs
1 September 2022 to 28 February 2025
Status
Finished
EU funding
€2.1m
Total cost
€3.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190168043

What the project is doing

In the project's own words, from its summary on CORDIS.

There is a major unmet need for effective and safe therapies for advanced peripheral arterial occlusive disease (PAOD) due to the high cardiovascular mortality, morbidity, and amputation rates in these patients. Aplagon is developing the first vascular injury -targeting product (APAC) for the local treatment of advanced PAOD. PAOD is caused by fatty deposits in lower limb arteries (atherosclerosis) that become inflamed (thromboinflammation), resulting in blood coagulation (atherothrombosis).

APAC uniquely targets these vessels, prevents further atherosclerosis and downregulates thromboinflammation, the main drivers of PAOD. Aplagon has completed preclinical proof-of-concept and toxicology studies and received a regulatory approval to enter clinical studies. Aplagon has an experienced, international team, and is supported by a renowned scientific advisory board. We are applying for EIC-funding to show the safety and efficacy of APAC in PAOD/CLI-patients, a major value inflection point.

Topics

Who is involved

OrganisationCityCountryRole
Aplagon OyHelsinkiFinlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI